Therapeutic Prospects in Preeclampsia – A Mini-Review
Background: Preeclapmsia (PE) is characterized by early onset symptoms such as elevated blood pressure, proteinuria and edema in the pregnant woman, and may result in seizures in the affected woman. Currently, there are no therapeutic drugs available to treat this condition, but there are interventions to regulate the symptoms based on the gestational period of the fetus, although the largely favored option is the delivery of the fetus and placenta.Objective: A search for biomolecules was conducted associated with PE so as to identify diagnostic markers and therapeutic leads.Results: The literature search resulted in the identification of biomolecules such as Corin and placental protein 13 (PP13), among others that are associated with PE. Thereby, giving an insight into the various mechanistic pathways involved in the causation of PE. However, it is also evident that PE cannot be solely attributed to any single mechanism but is due to an interplay of different factors that have led to the development of this disease condition.Conclusion: The identified biomarkers would ultimately help in understanding this complex disease and perhaps lead to the discovery of potential effective molecular targets for clinical trials, thereby providing a valuable therapeutic option for affected pregnant women.
No Supplementary Data
No Article Media